← Oncology Approval Tracker

FDA DECISION ·

Tagrisso + platinum chemotherapy

osimertinib with pemetrexed and platinum chemotherapy · AstraZeneca

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment of locally advanced or metastatic non-small cell lung cancer with an FDA test-confirmed EGFR exon 19 deletion or exon 21 L858R mutation, using osimertinib with pemetrexed and platinum chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The label added chemotherapy to frontline osimertinib as an option for common EGFR variants.

What research teams should watch

Coordinate oral and infusion treatment and record induction, maintenance, cumulative exposure and reasons for modification.

PRIMARY RECORDS

Sources